Trust Signals
- Evidence graded explicitly in the ledger table below. No claim presented with more confidence than the data supports.
- All cited statistics trace to named sources (original Geref labeling, published clinical trials, WADA prohibited list).
- Failure modes and what this peptide cannot do are covered in full, not buried.
- No affiliate links. No sponsored statements. Honest head-to-head comparisons where the peptide loses are included.
Key Takeaways
- Sermorelin is a 29-amino-acid fragment of endogenous GHRH that binds pituitary GHRH receptors to stimulate pulsatile GH release, unlike exogenous HGH which bypasses this axis entirely.
- The FDA-approved IV diagnostic dose was 1 mcg per kg; compounded subcutaneous protocols (200 to 500 mcg at bedtime) are off-label and lack large RCT support in adults.
- No published human pharmacokinetic study demonstrates clinically meaningful bioavailability for oral or sublingual sermorelin. Peptide bonds are cleaved by gastric proteases before absorption can occur.
- Serono voluntarily withdrew Geref in 2008 for commercial reasons, not safety reasons. Compounded sermorelin from 503A pharmacies remains legal with a prescription.
- WADA prohibits GHRH analogues including sermorelin. Any route of administration triggers this ban for tested athletes.
Direct Answer: Sermorelin Peptide Oral vs Injection
Injection wins decisively. Sermorelin is a 29-amino-acid peptide that gastric proteases degrade before systemic absorption occurs. No human pharmacokinetic data supports oral bioavailability. Subcutaneous injection delivers measurable GH-stimulating effect with documented clinical precedent. Oral and sublingual products are unvalidated and should not be assumed equivalent.Table of Contents
- What is sermorelin and how does it work mechanistically?
- Why does oral sermorelin not work?
- What do we actually know about injection pharmacokinetics?
- Evidence ledger: what the research proves and what it does not
- What most pages get wrong about sermorelin oral vs injection
- Head-to-head table: sermorelin vs HGH vs ipamorelin vs tesamorelin
- How to read a sermorelin product, COA, and compounding label
- Formulation and stability: why the rules exist
- Dosing and protocol reference
- FAQ
- Sources
What Is Sermorelin and How Does It Work Mechanistically?
Sermorelin acetate is the synthetic acetate salt of the first 29 amino acids of human growth hormone-releasing hormone (hGRH 1-29 NH2). Endogenous GHRH contains 44 amino acids; sermorelin retains the biologically active N-terminal segment that binds the pituitary GHRH receptor (GHRHR), a Gs-coupled GPCR. Receptor binding activates adenylyl cyclase, raises intracellular cAMP, and triggers GH synthesis and pulsatile secretion from somatotroph cells.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What this mechanism does NOT prove: stimulating GH secretion in a GH-sufficient adult does not automatically translate to meaningful improvements in lean mass, fat loss, or sleep quality. GH secretion is subject to negative feedback via somatostatin and IGF-1. Supraphysiologic stimulation encounters increasing somatostatinergic inhibition, which is one reason why simple dose escalation does not linearly raise IGF-1 levels.
Half-life: the plasma half-life of sermorelin after IV administration is short, estimated at roughly 10 to 20 minutes in published pharmacokinetic studies, consistent with rapid enzymatic degradation by serum endopeptidases. This short half-life is why subcutaneous depot absorption and timing relative to sleep (the dominant GH pulse period) matter clinically.
Why Does Oral Sermorelin Not Work?
The chemistry is straightforward and cannot be engineered around with basic formulation. Sermorelin is a linear 29-amino-acid peptide with standard peptide bonds (amide linkages between alpha-amino and alpha-carboxyl groups). The gastrointestinal environment presents three serial degradation steps:
- Gastric acid (pH 1.5 to 3.5): at low pH, acid-catalyzed hydrolysis begins cleaving peptide bonds, particularly at aspartyl-prolyl linkages. Sermorelin contains asp at position 8 and other acid-labile residues in its 29-mer sequence.
- Pepsin: a broad-specificity endopeptidase active in the stomach that cleaves peptide bonds preferentially adjacent to aromatic and hydrophobic residues. Sermorelin contains phenylalanine at position 6 (a pepsin-favorable cleavage site) and other susceptible residues.
- Pancreatic and brush-border proteases: trypsin (cleaves after Arg, Lys), chymotrypsin (cleaves after aromatic residues), and brush-border peptidases eliminate remaining fragments before paracellular absorption can occur at meaningful levels.
Sublingual delivery avoids first-pass hepatic metabolism but still exposes the peptide to salivary proteases (primarily proline-rich protein proteases and amylase-related enzymes) and mucosal aminopeptidases. The buccal mucosa has an absorption window primarily suited to small, lipophilic molecules below roughly 500 to 1000 Da. Sermorelin has a molecular weight of approximately 3357 Da, placing it far outside the range where passive mucosal diffusion is practical.
What Do We Actually Know About Injection Pharmacokinetics?
The strongest pharmacokinetic data for sermorelin comes from its original approval context: IV bolus for GH stimulation testing. The original Geref Diagnostic prescribing information (Serono, NDA 020237) documents that after IV administration of 1 mcg per kg, peak serum GH concentrations are typically observed within 15 to 45 minutes, with the test considered normal if GH exceeds 7 ng per mL (age and assay dependent).
For subcutaneous administration (the dominant compounding-era route), the absorption kinetics differ. SC injection creates a depot in the subcutaneous fat and connective tissue; absorption is slower and Cmax is lower than IV. Published studies on subcutaneous GHRH peptides (including native GHRH 1-44 and sermorelin) show that bioavailability via SC is substantially lower than IV, though exact percentages for sermorelin SC specifically are not uniformly established in the open literature. The clinical implication is that SC doses in practice are higher than the diagnostic IV dose to achieve a comparable stimulatory signal.
Timing matters: endogenous GH secretion peaks during slow-wave sleep (approximately 60 to 90 minutes after sleep onset), largely governed by hypothalamic GHRH pulses and decreased somatostatin tone. Administering sermorelin SC at bedtime is mechanistically rational because it amplifies a naturally occurring GH pulse rather than attempting to create a non-physiologic daytime peak.
Evidence Ledger: What the Research Proves and What It Does Not
| Claim | Best Evidence Type | Effect Direction | Confidence | Key Caveat |
|---|---|---|---|---|
| IV sermorelin raises serum GH in GH-deficient children | Human RCT, FDA pivotal trials (Geref NDA) | Positive | High | Approval was for GH-deficient pediatric patients, not GH-sufficient adults |
| Sermorelin SC stimulates GH release in adults | Small human pharmacodynamic studies, case series | Positive | Moderate | No large RCT for SC route; sample sizes typically under 50 |
| Oral sermorelin raises GH in humans | None (no published human PK or PD data) | No demonstrated effect | Very Low | Theoretical degradation basis; no clinical validation exists |
| Sublingual sermorelin raises GH in humans | None (no published human data) | No demonstrated effect | Very Low | Molecular weight and protease exposure preclude reliable absorption |
| Sermorelin SC improves body composition in GH-deficient adults | Small human studies, one Corpas et al. 1992 RCT (n=22) | Modest positive | Low to Moderate | Corpas et al. showed increased IGF-1 and lean mass in older men; not replicated at scale |
| Sermorelin SC improves body composition in GH-sufficient healthy adults | No published RCT | Unknown | Very Low | Extrapolated from GH-deficient data; GH feedback physiology differs in euGH adults |
| Tachyphylaxis with continuous daily sermorelin dosing | Mechanistic data, clinical observation; some small trials | Attenuation of response over time | Low to Moderate | Cycling protocols are widely recommended but not systematically validated in RCTs |
What Most Pages Get Wrong About Sermorelin Oral vs Injection
The majority of commercial and blog pages either ignore oral bioavailability entirely or make vague statements like "sublingual may be partially absorbed." Here are the specific points that get omitted:
1. "Oral peptides" often contain hydrolysates, not intact peptide. Some products labeled as oral sermorelin actually contain enzymatically pre-hydrolyzed fragments or amino acid blends. These have no GHRH receptor activity. A product that lists "sermorelin peptide" in a capsule is either ineffective intact peptide or a misleadingly named amino acid supplement. Neither raises GH.
2. The FDA regulatory gap matters to sourcing risk. Compounded sermorelin from 503A pharmacies is legal with a valid prescription. However, the FDA has increasingly scrutinized 503B outsourcing facility production of GHRH analogues. Patients and clinicians should verify that their source is a licensed 503A compounder with a real prescription, not a gray-market research chemical supplier. The difference is not just legal: it is a quality and sterility difference.
3. Tachyphylaxis is underreported in consumer content. Continuous daily SC dosing can downregulate GHRH receptor expression and increase somatostatin tone over weeks. The Corpas et al. (1992) study in older men used a pulsatile SC delivery approach specifically to reduce this phenomenon. Many current protocols recommend 5 days on, 2 days off or monthly cycling breaks, but these schedules are clinician-derived rather than RCT-derived.
4. IGF-1 is the real outcome biomarker, not GH. GH is pulsatile and difficult to measure meaningfully from a single draw. IGF-1 (produced hepatically in response to GH) is a more stable surrogate. Monitoring IGF-1 at baseline, 6 weeks, and 12 weeks is the practical way to assess whether a sermorelin SC protocol is producing any downstream effect. Oral or sublingual products that cannot raise IGF-1 measurably after 12 weeks are not working.
Head-to-Head: Sermorelin Injection vs Alternatives
| Comparator | Mechanism | Evidence Quality (adults) | Preserves Pituitary Axis? | Legal Status (US) | Where Sermorelin Loses |
|---|---|---|---|---|---|
| Sermorelin SC injection | GHRH receptor agonist, stimulates endogenous GH | Low to Moderate (small studies) | Yes | Compounded, prescription required | N/A (reference row) |
| Recombinant HGH (somatropin) SC injection | Direct GH replacement | High for GH-deficient adults (multiple RCTs) | No, suppresses endogenous production | FDA-approved for diagnosed GH deficiency; off-label anti-aging use is not approved | Sermorelin loses on effect magnitude in clearly deficient patients. HGH has far larger RCT evidence base. |
| Ipamorelin SC injection | GHS-R (ghrelin receptor) agonist | Very Low (minimal human RCTs published) | Yes, works synergistically with GHRH axis | Compounded, prescription required; under ongoing FDA scrutiny | Ipamorelin may have lower cortisol and prolactin side-effect profile; combination with CJC-1295 is widely used but less studied than sermorelin alone. |
| Oral sermorelin (any form) | Intended GHRH receptor agonism, actual: none demonstrable | None (no published human data) | Irrelevant if absorbed at negligible levels | Unregulated supplement or compounded product; not FDA-approved by oral route | Sermorelin oral loses to sermorelin injection on every clinically meaningful dimension. |
| Tesamorelin (Egrifta) SC injection | GHRH analogue (modified, longer-acting) | High for HIV-associated lipodystrophy (Phase III RCTs) | Yes | FDA-approved for HIV lipodystrophy only | Sermorelin loses to tesamorelin on evidence depth. Tesamorelin has the only large, replicated RCT evidence for a GHRH analogue in adults. |
How to Read a Sermorelin Product, COA, and Compounding Label
If you or a patient are evaluating a sermorelin product, apply this checklist before use:
- Identity confirmation: The COA should specify HPLC purity (target: greater than 98 percent for injectable grade) AND mass spectrometry identity confirmation. HPLC alone cannot distinguish sermorelin from a similar-chain peptide. MS confirms the exact molecular weight (3357.9 Da for sermorelin acetate) and fragmentation pattern.
- Sterility: Injectable products must pass USP 71 sterility testing. Confirm the lot number on the vial matches the COA lot number. If no sterility test is listed, the product is not confirmed safe for injection.
- Endotoxin: Bacterial endotoxins cause fever and injection-site inflammation. A compliant COA will list endotoxin results in EU per mg or EU per mL tested against the limits specified in USP 85 for the intended parenteral route. Confirm a passing result is explicitly stated and tied to the product lot.
- Concentration and volume math: A common compounded vial is 6 mg sermorelin in 3 mL bacteriostatic water (2 mg per mL or 2000 mcg per mL). A 300 mcg dose = 0.15 mL. Confirm your draw volume matches your intended dose before injecting.
- Red flags on an oral or sublingual sermorelin product label: vague claims like "bioavailable peptide complex," no COA available, "proprietary delivery matrix" without clinical citation, and absence of any controlled study reference. These are marketing language, not science.
Formulation and Stability: Why the Rules Exist
Why store at 2 to 8 degrees Celsius and avoid freeze-thaw cycles? Sermorelin in aqueous solution is subject to two primary degradation mechanisms. First, hydrolytic cleavage of peptide bonds is accelerated by temperature; Arrhenius kinetics predict that every 10-degree increase roughly doubles or more the rate of hydrolysis. Refrigeration slows this substantially. Second, aggregation: repeated freeze-thaw cycles cause ice crystal formation that disrupts the hydration shell around the peptide, promoting intermolecular beta-sheet stacking and particulate aggregation. Aggregated peptide loses receptor-binding activity and can also trigger immune reactions at the injection site.
Why bacteriostatic water and not sterile water? Bacteriostatic water for injection contains 0.9 percent benzyl alcohol as a preservative, which inhibits microbial growth in a multi-draw vial over the typical 28 to 30-day use period. Sterile water has no preservative and is appropriate for single-use reconstitution only. Using sterile water in a multi-draw vial creates contamination risk after the first draw breaks the septum seal.
What does degraded sermorelin look like? Visual inspection is not sufficient to detect peptide degradation. A clear, colorless solution can be heavily degraded at the molecular level. Cloudiness, particulates, or discoloration are definitive signs to discard, but a clean-looking solution is not a guarantee of potency. This is why shelf-life adherence matters more than appearance-based judgment.
Light sensitivity: Peptides with tryptophan, tyrosine, or phenylalanine residues (sermorelin contains Phe-6 and Tyr-1 in the native GHRH sequence portion) are susceptible to photo-oxidation under UV exposure. Store in the amber vial typically provided; do not leave reconstituted peptide on a countertop near a window.
Dosing and Protocol Reference
| Context | Route | Dose | Timing | Evidence Basis |
|---|---|---|---|---|
| GH stimulation diagnostic test | IV bolus | 1 mcg per kg body weight | Single dose, draw GH at 15, 30, 45, 60 min | FDA-approved (Geref Diagnostic); High evidence |
| GH deficiency treatment (pediatric, original Geref) | SC injection | 30 mcg per kg per day | Once daily at bedtime | FDA-approved (Geref); High evidence in pediatric GH deficiency |
| Adult wellness or anti-aging (compounded) | SC injection | 200 to 500 mcg | Once daily at bedtime, fasted | Small studies, Corpas et al. 1992 (n=22); Low to Moderate evidence; off-label |
| Oral or sublingual (any) | Oral or sublingual | Any dose | Any timing | No human evidence; Very Low confidence; not recommended |
FAQ
Is oral sermorelin effective?
No human pharmacokinetic data demonstrates meaningful oral bioavailability for sermorelin. Gastric and intestinal proteases degrade the 29-amino-acid peptide before systemic absorption. Oral or sublingual forms lack regulatory approval and have no published RCT evidence of GH-stimulating efficacy in humans.
What is the standard sermorelin injection dose?
The FDA-approved adult diagnostic dose was 1 mcg per kg body weight given as a single IV bolus. Compounded subcutaneous protocols commonly used in anti-aging clinics range from 200 to 500 mcg at bedtime, but these doses are not FDA-approved and lack large RCT support.
How quickly does sermorelin injection raise GH levels?
After IV administration, peak GH response typically occurs within 15 to 45 minutes per the original Geref Diagnostic prescribing information. Subcutaneous injection produces a slower, blunted peak compared to IV due to absorption lag, though precise SC pharmacokinetic data in published literature is limited.
Does sermorelin work differently from HGH injections?
Yes. Sermorelin is a GHRH analogue that stimulates endogenous pituitary GH release. Exogenous HGH bypasses the pituitary entirely. Sermorelin preserves the pulsatile, IGF-1-feedback-governed release pattern, whereas exogenous HGH suppresses endogenous production and raises baseline GH continuously.
Why did the FDA remove sermorelin from the market?
Sermorelin acetate (Geref) was voluntarily withdrawn by Serono in 2008 for commercial reasons, not safety concerns. It remains legal as a compounded preparation from licensed 503A pharmacies for individual patient prescriptions, though 503B outsourcing facilities face more restrictions.
Can sublingual sermorelin work as an alternative to injection?
Sublingual delivery avoids first-pass hepatic metabolism but still exposes the peptide to salivary and mucosal proteases. No published human study demonstrates adequate sublingual bioavailability for sermorelin. It remains an unvalidated route, and any claimed efficacy is based on extrapolation, not direct evidence.
What are the side effects of sermorelin injection?
The most common reported effects from published trials and the original Geref label include injection-site reactions, flushing, headache, and transient hyperglycemia. Tachyphylaxis with daily dosing has been reported in some protocols, which is why cycling is often recommended.
How should sermorelin be stored after reconstitution?
Reconstituted sermorelin should be refrigerated at 2 to 8 degrees Celsius and used within the timeframe specified by the compounding pharmacy, typically 28 to 30 days. Avoid freeze-thaw cycles after reconstitution, as repeated temperature cycling promotes aggregation and loss of biological activity.
Is sermorelin detectable on drug tests?
WADA prohibits GHRH analogues including sermorelin under the category of peptide hormones and growth factors. Urine and blood immunoassays can detect sermorelin and its metabolites. Athletes subject to anti-doping rules should treat sermorelin as a banned substance regardless of administration route.
How does sermorelin compare to ipamorelin for GH stimulation?
Sermorelin acts on GHRH receptors; ipamorelin acts on ghrelin or GHS receptors. Combining them produces synergistic GH pulses in animal and small human studies. Neither has large randomized trial evidence for body composition or anti-aging outcomes. Ipamorelin has a slightly lower reported cortisol and prolactin side-effect profile than older GHRPs.
What should I look for on a sermorelin COA?
A credible COA should confirm identity by HPLC and mass spectrometry, report purity above 98 percent, confirm sterility (USP 71 or equivalent), show endotoxin results within parenteral limits per USP 85, and list the specific lot number. Absence of MS confirmation is a red flag.
Who is a candidate for sermorelin therapy?
Sermorelin was FDA-approved as a diagnostic tool for GH deficiency in children and as a treatment for idiopathic GH deficiency. Adults with documented GH deficiency confirmed by stimulation testing are the clearest clinical candidates. Off-label wellness use in GH-sufficient adults lacks large RCT support.
Sources
- Serono Laboratories. Geref Diagnostic (sermorelin acetate for injection) prescribing information. NDA 020237. Withdrawn 2008.
- Serono Laboratories. Geref (sermorelin acetate for injection) prescribing information. Pediatric GH deficiency indication.
- Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. "Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men." J Clin Endocrinol Metab. 1992;75(2):530-535. PubMed PMID: 1639952.
- Thorner MO, Vance ML, Laws ER Jr, et al. "The anterior pituitary." In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia: Saunders; 1998.
- World Anti-Doping Agency. 2024 Prohibited List. Category S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. Available at wada-ama.org.
- U.S. Pharmacopeia. USP 71 Sterility Tests. USP-NF. Rockville, MD: USP.
- U.S. Pharmacopeia. USP 85 Bacterial Endotoxins Test. USP-NF. Rockville, MD: USP.
- FDA. Compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov guidance documents.
- Alba M, Fintini D, Bowers CY, Salvatori R. "Effects of combined administration of GHRH and a GH secretagogue in the GH-releasing hormone receptor-deficient little mouse." Am J Physiol Endocrinol Metab. 2005;289(5):E762-767. PubMed PMID: 15985451.
- Veldhuis JD, Bowers CY. "Human GH pulsatility: an ensemble property regulated by age and gender." J Endocrinol Invest. 2003;26(9):799-813.